Showing results (161-170 of 211) with videos related to

Sort By:
Pageof 22
The New England Journal of Medicine|December 11, 2012
Cardiovascular events and intensity of treatment in polycythemia veraRoberto Marchioli, Guido Finazzi, Giorgina Specchia, et al.
Oncotarget|November 21, 2017
The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemiaSara Galimberti, Cristina Bucelli, Elena Arrigoni, et al.
Frontiers in Oncology|June 15, 2018
Residual Peripheral Blood CD26<sup>+</sup> Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free RemissionMonica Bocchia, Anna Sicuranza, Elisabetta Abruzzese, et al.
Leukemia Research|August 19, 2015
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patientsMassimo Breccia, Fabio Efficace, Simona Sica, et al.
British Journal of Haematology|July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patientsFrancesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
Annals of Hematology|July 18, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study designValerio De Stefano, Francesco Passamonti, Francesca Palandri, et al.
Annals of Hematology|December 6, 2018
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinibMassimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, et al.
Blood Cancer Journal|June 9, 2018
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B<sub>2</sub> assay as an evaluation tool of different aspirin dosing regimens in the clinical settingValerio De Stefano, Bianca Rocca, Alberto Tosetto, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Leukemia Research|June 3, 2026
Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phaseRoberto Latagliata, Novella Pugliese, Dorela Lame, et al.
Pageof 22